secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039782
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors
------------------------------------------------------------------------

- Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.
- Justin Gover was founding CEO of GW Pharma (sold for $7.2B) and led development of Epidiolex for epilepsy.
- Appointments effective August 8, 2023; both will receive standard non-employee director compensation.
- Their expertise aligns with Xenon's advancing XEN1101 in Phase 3 epilepsy trials and Phase 2 MDD study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/xene-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer